|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-1-31
|
|
pubmed:abstractText |
Posttransplant lymphoproliferative disease (PTLD), driven by the presence of Epstein-Barr virus (EBV), is becoming an increasingly important clinical problem after solid organ transplantation. The use of immunosuppressive therapy leads to the inhibition of the cytotoxic T cells that normally control the EBV latently infected B cells. The prognosis for many patients with PTLD is poor, and the optimal treatment strategy is not well defined.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
271-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11821743-B-Lymphocytes,
pubmed-meshheading:11821743-Cell Death,
pubmed-meshheading:11821743-Cell Line,
pubmed-meshheading:11821743-Cell Transformation, Viral,
pubmed-meshheading:11821743-Enzyme Inhibitors,
pubmed-meshheading:11821743-G2 Phase,
pubmed-meshheading:11821743-Herpesvirus 4, Human,
pubmed-meshheading:11821743-Histone Deacetylase Inhibitors,
pubmed-meshheading:11821743-Humans,
pubmed-meshheading:11821743-Hydroxamic Acids,
pubmed-meshheading:11821743-Lymphocyte Activation,
pubmed-meshheading:11821743-Lymphoproliferative Disorders,
pubmed-meshheading:11821743-Mitosis,
pubmed-meshheading:11821743-Organ Transplantation,
pubmed-meshheading:11821743-Virus Replication
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.
|
|
pubmed:affiliation |
Queensland Institute of Medical Research and University of Queensland Joint Oncology Program, Herston 4029, Brisbane, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
